异动解读｜科伦博泰生物盘中上涨3.78%，核心产品TROP2 ADC新增适应症上市申请获受理

行情直击07-31

7月31日，科伦博泰生物盘中上涨3.78%，报499.0港元/股，成交额5879.98万港元。

消息面上，公司于7月30日公告，核心产品芦康沙妥珠单抗用于PD-L1综合阳性评分＜10或早期接受过PD-1/PD-L1抑制剂的复发或转移性三阴性乳腺癌一线治疗的新增适应症上市申请已获NMPA受理，并纳入优先审评审批程序。这是芦康沙妥珠单抗第六项获受理的适应症上市申请，该产品已在中国获批4项适应症。此外，合作方默沙东近期启动了芦康沙妥珠单抗联合PD-1/VEGF双抗的II期临床研究，进一步拓展联合用药布局。

（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/1180795516?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-31 10:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180795516","market":"hk","top_or_hot":-1,"title":"异动解读｜科伦博泰生物盘中上涨3.78%，核心产品TROP2 ADC新增适应症上市申请获受理","media":"行情直击","content":"<p><p>7月31日，科伦博泰生物盘中上涨3.78%，报499.0港元/股，成交额5879.98万港元。</p><p>消息面上，公司于7月30日公告，核心产品芦康沙妥珠单抗用于PD-L1综合阳性评分＜10或早期接受过PD-1/PD-L1抑制剂的复发或转移性三阴性乳腺癌一线治疗的新增适应症上市申请已获NMPA受理，并纳入优先审评审批程序。这是芦康沙妥珠单抗第六项获受理的适应症上市申请，该产品已在中国获批4项适应症。此外，合作方默沙东近期启动了芦康沙妥珠单抗联合PD-1/VEGF双抗的II期临床研究，进一步拓展联合用药布局。</p><p>（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读｜科伦博泰生物盘中上涨3.78%，核心产品TROP2 ADC新增适应症上市申请获受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读｜科伦博泰生物盘中上涨3.78%，核心产品TROP2 ADC新增适应症上市申请获受理\n</h2>\n\n<h4 class=\"meta\">\n\n2026-07-31 10:04 北京时间&nbsp;&nbsp;&nbsp;<strong>行情直击</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>7月31日，科伦博泰生物盘中上涨3.78%，报499.0港元/股，成交额5879.98万港元。消息面上，公司于7月30日公告，核心产品芦康沙妥珠单抗用于PD-L1综合阳性评分＜10或早期接受过PD-1/PD-L1抑制剂的复发或转移性三阴性乳腺癌一线治疗的新增适应症上市申请已获NMPA受理，并纳入优先审评审批程序。这是芦康沙妥珠单抗第六项获受理的适应症上市申请，该产品已在中国获批4项适应症。此外，...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06990","symbol_name":"科伦博泰生物","start_time":0,"source_url":"","article_id":"1180795516","we_media_id":"1059448697","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180795516","pubTimestamp":1785463495,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"行情直击","introduction":"个股异动一手消息解读","home_visible":1,"id":"1059448697","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"7月31日，科伦博泰生物盘中上涨3.78%，报499.0港元/股，成交额5879.98万港元。消息面上，公司于7月30日公告，核心产品芦康沙妥珠单抗用于PD-L1综合阳性评分＜10或早期接受过PD-1/PD-L1抑制剂的复发或转移性三阴性乳腺癌一线治疗的新增适应症上市申请已获NMPA受理，并纳入优先审评审批程序。此外，合作方默沙东近期启动了芦康沙妥珠单抗联合PD-1/VEGF双抗的II期临床研究，进一步拓展联合用药布局。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"06990":"科伦博泰生物"},"translate_title":"Interpretation of the change | Kelunbotai Biotech rose by 3.78% in the intraday session, and the marketing application for the new indication of the core product TROP2 ADC was accepted","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":1},"content_text":"7月31日，科伦博泰生物盘中上涨3.78%，报499.0港元/股，成交额5879.98万港元。消息面上，公司于7月30日公告，核心产品芦康沙妥珠单抗用于PD-L1综合阳性评分＜10或早期接受过PD-1/PD-L1抑制剂的复发或转移性三阴性乳腺癌一线治疗的新增适应症上市申请已获NMPA受理，并纳入优先审评审批程序。这是芦康沙妥珠单抗第六项获受理的适应症上市申请，该产品已在中国获批4项适应症。此外，合作方默沙东近期启动了芦康沙妥珠单抗联合PD-1/VEGF双抗的II期临床研究，进一步拓展联合用药布局。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1180795516","isCrawlerRequest":true}